Zynext Ventures invests in Feldan for intracellular drug delivery

Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has announced an investment in Feldan Therapeutics, a Canada-based pharmaceutical company focused on intracellular drug delivery. This investment aims to support Feldan in developing treatments for dermatological and pulmonary diseases using its proprietary Shuttle peptide technology. Feldan's lead product, FLD-103, is currently in Phase 1/2a clinical trials for treating basal cell carcinoma (BCC), offering a non-surgical treatment option that enhances patient outcomes and improves their quality of life. Zynext Ventures' investment aligns with its strategy to invest in disruptive innovations and next-generation therapeutics, while Zydus Lifesciences seeks to address critical healthcare gaps through novel therapeutics. Zydus Lifesciences is listed on the BSE with stock code ZYDUSLIFE.